Table1.
Characteristics of patients by treatment group
| Warfarin (N = 15) | NOA (N = 15) | p | |
|---|---|---|---|
| Age (years) | 79 ± 10 | 84 ± 7 | 0.158 |
| Men (n, %) | 11 (73.3) | 9 (60.0) | 0.700 |
| Higher education (n, %) | 8 (53.3) | 5 (33.3) | 0.462 |
| Retired (n, %) | 13 (86.7) | 14 (93.3) | 1.000 |
| Married (n, %) | 10 (66.7) | 5 (33.3) | 0.143 |
| Living alone (n, %) | 1 (6.7) | 4 (26.7) | 0.180 |
| IADL—Drugs (n, %) | 12 (80.0) | 8 (53.0) | 0.245 |
| Bleeding (n, %) | 4 (26.7) | 2 (13.3) | 0.651 |
| CHF (n, %) | 7 (46.7) | 6 (40.0) | 1.000 |
| Cognitive impairment (n, %) | 4 (26.7) | 6 (40.0) | 0.291 |
| CVD (n, %) | 3 (20.0) | 6 (40.0) | 0.427 |
| Diabetes (n, %) | 3 (20.0) | 1 (6.7) | 0.598 |
| Hypertension (n, %) | 11 (73.3) | 13 (86.7) | 0.651 |
| Myocardial infarction (n, %) | 6 (40.0) | 2 (13.3) | 0.215 |
| Renal failure (n, %) | 3 (20.0) | 2 (13.3) | 1.000 |
| CHA2DS2-VASc (score) | 4.2 ± 1.6 | 4.4 ± 1.3 | 0.711 |
| HASBLED (score) | 2.9 ± 1.3 | 3.0 ± 0.8 | 0.734 |
| Pacemaker (n, %) | 1 (6.7) | 4 (26.7) | 0.330 |
| ASA (n, %) | 3 (20.0) | 0 (0.0) | 0.224 |
| Thienopyridines (n, %) | 2 (13.3) | 1 (6.7) | 1.000 |
| Drugs (n) | 7.4 ± 3.3 | 5.9 ± 3.7 | 0.236 |
Higher education high school diploma or university degree, IADLDrugs patients who do not manage therapy by themselves, CHF chronic heart failure, Cognitive impairment mild cognitive impairment, CVD TIA/Stroke, ASA aspirin